Leading the Way in Life Science Technologies

GEN Exclusives

More »

Feature Articles

More »
Sep 15, 2008 (Vol. 28, No. 16)

Users Are Sold on Single-Use Systems

Survey of Adoption Trends Shows Burgeoning Usage Across All Sectors of Industry

  • Reasons for Restricting Usage

    We tested 17 reasons why biopharmaceutical manufacturers and CMOs might not expand their use of disposables. Figure 3 shows the top five. The primary concern was over leachables and extractables where 75.4% of respondents agree or strongly agree that L&E issues are restricting the use of disposables. This compares with 63% of respondents last year. Part of this is the result of the increased use of disposables, which has, in turn, increased awareness and FDA interest.

    The second greatest concern was the fact that participants had “already invested in equipment for current system” (65.2% agree or strongly agree). Other factors included:

  • becoming vendor-dependent (single-source issues)

  • breakage of bags and loss of production materials

  • investment in validation

  • lack of uniform standards

  • regulatory guidance on leachables and extractables

  • lack of cost data

  • CMOs vs. Biotherapeutic Developers

    The primary reason both CMOs and biotherapeutic developers might not expand their use of disposables was concern over L&E issues (70.6% for CMOs and 75.9% for biotherapeutic developers).

    When comparing differences between CMOs and biotherapeutic developers, a significantly greater number of biotherapeutic developers indicated that the primary reason they would restrict expanded use of disposables is because they have already invested in equipment for their current system (67.9% for biotherapeutic developers vs. 37.5% for CMOs). This is likely because CMOs can generally be more flexible; they can also pass many of these direct costs on to the client. Lack of lifetime operating cost data comparing stainless steel to disposable options is more of a concern to biotherapeutic developers.

    Other differences between CMOs and biotherapeutic developers were found, from “lack of disposable equipment that meets process requirements” (where CMOs were more concerned), to “material incompatibility,” “lack of clear guidance on leachables and extractables,” and “breakage of bags” (where biotherapeutic developers were more concerned).

  • Current Spending

    Bioreactors tend to be one of the most expensive disposable items, and they were the item on which respondents spent the most in 2007. On average, respondents spent $212,959 per facility annually on these products. This is a change from last year’s top item, which was “media bags—filled wet” on which facilities spent an average of $164,313 in 2006.


  • Readers' Comments

    Posted 10/01/2008 by Product Manager Membrane Chromatography at Sartorius

    The article gave a nice overview about the motivations and concerns of our customers using single-use products.
    Very important for me that the market dynamic has been quantified the first time. Thanks to E.S.


    Related content

    Be sure to take the GEN Poll

    Scientifically Studying Ecstasy

    MDMA (commonly known as the empathogen “ecstasy”) is classified as a Schedule 1 drug, which is reserved for compounds with no accepted medical use and a high abuse potential. Two researchers from Stanford, however, call for a rigorous scientific exploration of MDMA's effects to identify precisely how the drug works, the data from which could be used to develop therapeutic compounds.

    Do you agree that ecstasy should be studied for its potential therapeutic benefits?

    More »